DigitalOptic-NobleBio, Commercialization of COVID-19 Diagnostic Specimen Kit for Pets 추진

[Asia Economy Reporter Yoo Hyun-seok] As Seoul City announced that it will conduct COVID-19 testing for companion animals, Digital Optic is accelerating the expansion of its diagnostic bio business through the development of diagnostic specimen kits for companion animals.

On the 9th, Digital Optic announced that it will commercialize a COVID-19 diagnostic specimen collection kit for companion animals in collaboration with its largest shareholder, Noble Bio.

After a cat was confirmed to be infected with COVID-19 for the first time in Korea last month, the government instructed all provinces and cities nationwide to establish guidelines for diagnostic testing of companion animals. In response, Seoul City plans to conduct COVID-19 tests on companion animals, specifically dogs and cats, starting from the 8th.

To respond to market changes, Digital Optic is developing a COVID-19 diagnostic specimen collection kit for companion animals together with Noble Bio. A company official stated, “Based on the technological capabilities of Noble Bio, the world’s number one producer of swabs, an essential product for COVID-19 diagnosis, we expect to commercialize a COVID-19 diagnostic specimen kit exclusively for companion animals in the near future. Although the possibility of transmission from companion animals to humans is low even if they contract COVID-19, diagnosis is necessary for prevention, and demand for companion animal specimen collection kits will continue to increase.”

He added, “In addition to the COVID-19 diagnostic specimen collection kit exclusively for companion animals, we are also developing a saliva collection kit that enhances convenience and accuracy. We anticipate that related orders will expand through the commercialization of new specimen collection kits.”

This content was produced with the assistance of AI translation services.